• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

OMNY Health Launches GLP-1 Data Network to Advance Research

by Jasmine Pennic 08/27/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– OMNY Health, a healthcare ecosystem specializing in data partnerships, today announced the launch of its GLP-1 data network. 

– The GLP-1 data network aims to democratize access to healthcare data and empower researchers, clinicians, and life sciences companies to gain valuable insights into GLP-1 therapies.

Addressing Data Gaps in GLP-1 Research

Despite the growing use of GLP-1 agonists, there remains a significant lack of comprehensive data on their effectiveness and long-term effects. OMNY Health’s GLP-1 data network addresses this gap by providing access to curated EMR data from over 645,000 patients. This data includes information on patient demographics, SDOH factors, and clinical outcomes, enabling researchers to conduct more robust studies.

Key Features of the GLP-1 Data Network:

  • Diverse patient population: The network includes data from patients across various age ranges, race/ethnicity, regions, and provider/payer types.
  • SDOH data: The network captures important SDOH factors, such as economic insecurity, food insecurity, and social isolation, which can significantly impact health outcomes.
  • Pediatric data: The network includes valuable information on pediatric use of GLP-1 therapies, which is becoming increasingly important due to the FDA’s recent approval for this population.

Enabling Data-Driven Insights

OMNY Health’s GLP-1 data network empowers researchers and clinicians to:

  • Diversify clinical trials: Access a broader patient population for more representative studies.
  • Understand medication interactions: Gain insights into how GLP-1s interact with other medications.
  • Strengthen treatment outcomes: Identify effective treatment strategies based on patient characteristics and SDOH factors.

The Importance of Data-Driven Decision Making

The availability of high-quality healthcare data is essential for driving innovation and improving patient outcomes. By providing access to a comprehensive GLP-1 data network, OMNY Health is helping to advance research and inform clinical decision-making in this important area.

“GLP-1 therapies are transforming the treatment landscape across multiple conditions beyond diabetes and obesity in profound ways. The systemic impact of these medications underlines the need for more comprehensive data to fully understand how these therapies affect patients as a whole,” said Dr. Mitesh Rao, CEO of OMNY Health. “By democratizing data partnerships between life sciences companies and health systems, we can enable more in-depth clinical research that will fuel healthcare innovation and revolutionize the potential impact of GLP-1’s for years to come.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: GLP-1

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |